H. Hagihara

发表

Y. Nakanishi, H. Shiraha, Shin-ichi Nishina, 2011, BMC Cancer.

Serum oxidative–anti‐oxidative stress balance is dysregulated in patients with hepatitis C virus‐related hepatocellular carcinoma

K. Kuwaki, H. Hagihara, A. Takaki, 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

The diagnosis of hypovascular hepatic lesions showing hypo-intensity in the hepatobiliary phase of Gd-EOB- DTPA-enhanced MR imaging in high-risk patients for hepatocellular carcinoma.

H. Shiraha, K. Kuwaki, H. Hagihara, 2013, Acta medica Okayama.

Prognostic importance of fucosylated alpha‐fetoprotein in hepatocellular carcinoma patients with low alpha‐fetoprotein

H. Shiraha, K. Kuwaki, H. Hagihara, 2011, Journal of gastroenterology and hepatology.

Prognotic impact of serum follistatin in patients with hepatocellular carcinoma

H. Shiraha, K. Kuwaki, H. Hagihara, 2013, Journal of gastroenterology and hepatology.

Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma

H. Shiraha, K. Kuwaki, H. Hagihara, 2011, Journal of gastroenterology and hepatology.

Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma

H. Shiraha, K. Kuwaki, H. Hagihara, 2012, Journal of Gastroenterology.

Monitoring serum proangiogenic cytokines from hepatocellular carcinoma patients treated with sorafenib

H. Shiraha, H. Hagihara, A. Takaki, 2018, Journal of gastroenterology and hepatology.

Evaluation of the effect of sorafenib using serum NX‐des‐γ‐carboxyprothrombin in patients with hepatocellular carcinoma

H. Shiraha, K. Kuwaki, H. Hagihara, 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

Effect of Previous Interferon Treatment on Outcome After Curative Treatment for Hepatitis C Virus-Related Hepatocellular Carcinoma

K. Kuwaki, H. Hagihara, J. Toshimori, 2012, Digestive Diseases and Sciences.

Fucosylated-hemopexin and HCC 1 1 Clinical utility of serum Fucosylated-hemopexin in Japanese patients with Hepatocellular Carcinoma

H. Shiraha, K. Kuwaki, H. Hagihara, 2013 .

Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma

H. Shiraha, K. Kuwaki, H. Hagihara, 2011, International Journal of Clinical Oncology.

Clinical utility of serum fucosylated hemopexin in Japanese patients with hepatocellular carcinoma

H. Shiraha, K. Kuwaki, H. Hagihara, 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

Evolution of prognostic factors in hepatocellular carcinoma in Japan

H. Shiraha, K. Kuwaki, H. Hagihara, 2010, Alimentary pharmacology & therapeutics.

Clinical utility of high-throughput glycome analysis in patients with pancreatic cancer

H. Shiraha, K. Kuwaki, H. Hagihara, 2013, Journal of Gastroenterology.

Y. Nakanishi, H. Shiraha, Shin-ichi Nishina, 2012, International journal of cancer.

The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis

H. Shiraha, K. Kuwaki, H. Hagihara, 2013, Journal of Gastroenterology.

Mixed HCV Infection of Genotype 1B and Other Genotypes Influences Non-response during Daclatasvir + Asunaprevir Combination Therapy.

H. Hagihara, A. Takaki, Y. Takeuchi, 2018, Acta medica Okayama.

Hepatocellular carcinoma occurring in hepatobiliary fibropolycystic disease

H. Shiraha, K. Kuwaki, H. Hagihara, 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma

M. Honda, H. Shiraha, K. Kuwaki, 2013, British Journal of Cancer.

Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma

H. Shiraha, K. Kuwaki, H. Hagihara, 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

The Efficacy and Safety of Steroids for Preventing Postembolization Syndrome after Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma.

H. Shiraha, K. Kuwaki, H. Hagihara, 2019, Acta medica Okayama.

The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab

H. Shiraha, H. Hagihara, A. Takaki, 2023, Cancer medicine.

Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma

H. Shiraha, K. Kuwaki, H. Hagihara, 2012, Journal of Gastroenterology.

Hepatocellular carcinoma recurrence in HCV patients treated with direct-acting antivirals after curative treatment

H. Hagihara, Shinichiro Nakamura, K. Nouso, 2019, Hepatoma Research.